Royalty Pharma (RPRX) to Release Quarterly Earnings on Tuesday

Royalty Pharma (NASDAQ:RPRX) will likely be issuing its quarterly earnings data before the market opens on Tuesday, February 11th. Analysts expect the company to announce earnings of $0.99 per share and revenue of $743.60 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Royalty Pharma Trading Down 0.8 %

NASDAQ RPRX opened at $31.33 on Tuesday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.54. The company has a 50-day simple moving average of $27.34 and a 200-day simple moving average of $27.53. The firm has a market capitalization of $18.46 billion, a PE ratio of 16.23 and a beta of 0.49. Royalty Pharma has a one year low of $24.05 and a one year high of $32.21.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be issued a $0.22 dividend. The ex-dividend date of this dividend is Friday, February 21st. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a dividend yield of 2.81%. Royalty Pharma’s dividend payout ratio (DPR) is 43.52%.

Analyst Ratings Changes

RPRX has been the topic of several recent analyst reports. Citigroup cut their target price on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. TD Cowen raised Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. Finally, StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $41.67.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.